Liver cancer, primarily hepatocellular carcinoma (HCC), exhibits highly heterogeneous
histological and molecular aberrations across tumors and within individual tumor nodules …

Liquid biopsy, specifically the analysis of circulating tumor DNA (ctDNA), offers a non-
invasive approach for hepatocellular carcinoma (HCC) diagnosis and management …

Introduction Advances in genomics have facilitated the application of cell-free DNA (cfDNA)
and circulating tumor DNA (ctDNA) in phase II and phase III clinical trials. The various …

Purpose: Detecting residual disease is a critical clinical requirement in the perisurgical
management of patients with resectable hepatocellular carcinoma (HCC). Previous studies …

Background Estrogen receptors express in nearly 70% of breast cancers (ER-positive).
Estrogen receptor alpha plays a fundamental role as a significant factor in breast cancer …

Gastrointestinal (GI) cancers account for one-fourth of the global cancer incidence and are
incriminated to cause one-third of cancer-related deaths. GI cancer includes esophageal …

Hepatocellular carcinoma (HCC) accounts for the majority of liver cancers and is driven by a
multitude of viral, metabolic, and lifestyle factors initiating liver injury that subsequently …

PURPOSE Next-generation sequencing (NGS) of tumor-derived, circulating cell-free DNA
(cfDNA) may aid in diagnosis, prognostication, and treatment of patients with hepatocellular …

Nowadays, hepatocellular carcinoma (HCC) is still a major threat to human health globally,
with a disappointing prognosis. Regular monitoring of patients at high risk, utilizing …

Liver cancer caused by the hepatitis B virus (HBV) is the third most common cancer-related
cause of death worldwide. Early detection of HBV-caused hepatic tumors increases the …